Clinical Trial of Exercise in Patients With Spinal Muscular Atrophy (SMA)
Randomized, Controlled Clinical Trial of Exercise in Patients With Spinal Muscular Atrophy (SMA)
2 other identifiers
interventional
14
1 country
1
Brief Summary
This study is being conducted to test whether exercise can be effectively used as an intervention to treat Spinal Muscular Atrophy (SMA). In order to answer this question, the investigators will enroll 14 subjects with SMA between ages 8 and 50 and ask them to complete an 18 month training schedule. At some points subjects will be asked to closely follow a specific training regimen and at other points they may be asked to exercise in the same manner they do normally. The exercises they will be asked to perform include biking on a stationary cycle and lifting hand weights. Subjects will be asked to come in to the clinic seven times over the course of the study to perform tests. These tests include motor function measures, a physical exam, questionnaires, a exercise capacity test which involves riding a stationary bicycle, and test where the subject is asked to walk as far as they can in six minutes. The main goal of the study is to see if the subjects who participate in the exercise protocol have larger increases in the distance they can walk in six minutes than those who do not.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Dec 2010
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 14, 2010
CompletedFirst Posted
Study publicly available on registry
July 20, 2010
CompletedStudy Start
First participant enrolled
December 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2014
CompletedAugust 12, 2016
August 1, 2016
3.7 years
July 14, 2010
August 11, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Distance walked in the Six Minute Walk Test (6MWT).
Up to 19 months
Study Arms (2)
Exercise
EXPERIMENTALMuscle strengthening program using weights and resistance bands in combination with a home based cycle ergometry program. The home-based exercise program will be performed up to 5 times weekly.
Typical Activity
NO INTERVENTIONSubjects in this group will be asked to maintain their typical daily activity. Those assigned to this arm will be given the opportunity to join the intervention arm seven months after their screening visit.
Interventions
Muscle strengthening program using hand weights and resistance bands in combination with a home based cycle ergometry. This home-based exercise program will be performed up to 5 times weekly. Each session will consist of up to 30 minutes of cycling and 30 minutes of strengthening.
Eligibility Criteria
You may qualify if:
- Weakness and hypotonia consistent with the clinical diagnosis of SMA type 3, i.e. having achieved the ability to walk independently
- Laboratory documentation of homozygous absence of SMN1 exon 7
- ability to walk at least 25 meters without assistance
- Aged 8 to 50 years at the time of enrollment
- Ability to tread the stationary cycle ergometer
- Written informed consent of patient (if ≥ 18 years of age) or parents/guardian (if \< 18 years of age), and assent for participants who are of minor age.
You may not qualify if:
- Inability to walk independently at least 25 meters
- Any acute co-morbid condition interfering with study participation in the judgment of the investigators within 7 days of enrollment including bacterial infection, viral infectious process, food poisoning, temperature \> 99.0ºF, need for acute treatment or observation due to any other reason, as judged by the investigator; patient can be included after resolution of the acute event
- Use of investigational medications intended for the treatment of SMA including riluzole, valproic acid, hydroxyurea, oral use of albuterol, sodium phenylbutyrate, butyrate derivatives, creatine, carnitine, growth hormone, anabolic steroids, or agents with known or presumed histone deacetylase (HDAC) inhibition, within 30 days prior to study entry. After signing informed consent, participants may discontinue prohibited medications and will then qualify for a screening visit after the 30 day wash-out period
- Inability to meet study visit requirements, or cooperate reliably with functional testing and exercise protocol
- Coexisting medical conditions that contraindicate travel, testing or moderate intensity exercise
- Pregnant or breastfeeding women, or those intending to become pregnant during the course of the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Columbia University SMA Clinical Research Center
New York, New York, 10032, United States
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Darryl C De Vivo, MD
Columbia University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Sidney Carter Professor of Neurology and Professor of Pediatrics
Study Record Dates
First Submitted
July 14, 2010
First Posted
July 20, 2010
Study Start
December 1, 2010
Primary Completion
August 1, 2014
Study Completion
August 1, 2014
Last Updated
August 12, 2016
Record last verified: 2016-08